Furthermore, recent reports have shown that bevacizumab can improve intra-tumor penetration of other chemotherapeutic agents, such as etoposide and cisplatin in breast cancer [101, 102], carboplatin and paclitaxel in NSCLC [55, 103], and erlotinib in EGFR positive cancers [104], perhaps by normalizing angiogenesis at the tumor site. Here, EGFR is linked to neoplasm.